Quantbot Technologies LP Trims Position in Omnicell, Inc. (NASDAQ:OMCL)

Quantbot Technologies LP decreased its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 14.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,581 shares of the company’s stock after selling 3,100 shares during the quarter. Quantbot Technologies LP’s holdings in Omnicell were worth $810,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. CWM LLC lifted its position in shares of Omnicell by 68.2% in the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after purchasing an additional 1,236 shares during the period. Diversified Trust Co boosted its position in Omnicell by 3.3% during the 2nd quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock valued at $416,000 after acquiring an additional 494 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Omnicell by 61.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock worth $16,240,000 after acquiring an additional 228,093 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Omnicell by 248.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its stake in shares of Omnicell by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock valued at $625,000 after purchasing an additional 600 shares during the period. Institutional investors own 97.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on OMCL shares. Wells Fargo & Company upped their price target on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. JPMorgan Chase & Co. increased their price target on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Craig Hallum boosted their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Wednesday, November 27th. Finally, Bank of America reissued a “neutral” rating and issued a $57.00 price target (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Omnicell presently has a consensus rating of “Hold” and an average target price of $52.00.

Omnicell Stock Performance

Shares of Omnicell stock opened at $46.59 on Monday. The company has a 50-day simple moving average of $44.55 and a two-hundred day simple moving average of $38.05. The stock has a market capitalization of $2.16 billion, a PE ratio of -119.46, a price-to-earnings-growth ratio of 35.40 and a beta of 0.81. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.74.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.